Nanotechnology-based drug delivery to improve the therapeutic benefits of NRF2 modulators in cancer therapy

Sezgin-Bayindir, Zerrin (author), Losada-Barreiro, Sonia (author), Bravo-Díaz, Carlos (author), Sova, Matej (author), Kristl, Julijana (author), Saso, Luciano (author)

The disadvantages of conventional anticancer drugs, such as their low bioavailability, poor targeting efficacy, and serious side effects, have led to the discovery of new therapeutic agents and potential drug delivery systems. In particular, the introduction of nano-sized drug delivery systems (NDDSs) has opened new horizons for effective cancer treatment. These are considered potential systems that provide deep tissue penetration and specific drug targeting. On the other hand, nuclear factor erythroid 2-related factor 2 (NRF2)-based anticancer treatment approaches have attracted tremendous attention and produced encouraging results. However, the lack of effective formulation strategies is one of the factors that hinder the clinical application of NRF2 modulators. In this review, we initially focus on the critical role of NRF2 in cancer cells and NRF2-based anticancer treatment. Subsequently, we review the preparation and characterization of NDDSs encapsulating NRF2 modulators and discuss their potential for cancer therapy.

• Language: English
• Keywords: NRF2 modulators, anticancer agents, nanoparticles, drug delivery, drug targeting
• Work type: Article
• Typology: 1.02 - Review Article
• Organization: FFA - Faculty of Pharmacy
• Publication status: Published
• Publication version: Version of Record
• Year: 2021
• Number of pages: 20 str.
• Numbering: Vol. 10, iss. 5, art. 685
• PID: 20.500.12556/RUL-135341
• UDC: 620.3:616-006-085
• ISSN on article: 2076-3921
• DOI: 10.3390/antiox10050685
• COBISS.SI-ID: 61560579
• Publication date in RUL: 08.03.2022

Record is a part of a journal

• Title: Antioxidants
• Shortened title: Antioxidants
• Publisher: MDPI
• ISSN: 2076-3921
• COBISS.SI-ID: 522976025

Licences

• License: CC BY 4.0, Creative Commons Attribution 4.0 International
• Link: http://creativecommons.org/licenses/by/4.0/
• Description: This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
• Licensing start date: 01.05.2021

Secondary language

• Language: Slovenian
• Keywords: nanodelci, NRF modulatorji, terapevtska uporaba zdravil, rak, zdravljenje raka, tarčno zdravljenje, nanotehnologija